Key statistics dashboard for Delcath Systems, Inc. (DCTH). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects.
Stock Data
| Price | $16.22 |
| Market Cap | $560M |
| Beta | 0.43 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | 1477.27 |
| Price / Book | 4.81 |
| P/S | 5.88 |
| P/FCF | 32.04 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 87.05% |
| EBIT Margin | 1.35% |
| EBITDA Margin | 1.78% |
| Operating Margin | -1.90% |
| Net Margin | 0.56% |
Financial Health
| Current Ratio | 9.83 |
| Quick Ratio | 8.95 |
| Cash Ratio | 3.58 |
| Debt / Equity | 0.02 |
| Debt / Assets | 1.80% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 2.66 |
| Book Value per share | 3.38 |
| Cash per share | 2.67 |
| FCF per share | 0.49 |
| Tangible Book Value per share | 3.38 |
| Dividend per share | 0.00 |
Related companies: AGL · BWAY · CERS · MASS · NAKA · NPCE · RXST
Explore sector: Healthcare · Medical - Devices
More sections of DCTH: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks